Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma BiotechnologyPBYI -3.03%53 EV-to-OCF is 5.71 as of Aug. 04, 2026, which is 11% above its 10-year median of 5.16. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.34 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,411 Biotechnology companies, Puma Biotechnology ranks worse than 81.01% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Puma Biotechnology's Enterprise Value is $305.8 Mil.
Puma Biotechnology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $53.6 Mil. Therefore, Puma Biotechnology's EV-to-OCF for today is 5.71.
The historical rank and industry rank for Puma Biotechnology's EV-to-OCF or its related term are showing as below:
PBYI'
s EV-to-OCF Range Over the Past 10 Years
Min: -427.82 Med: 5.16 Max: 668.22
Current: 5.71
During the past 13 years, the highest EV-to-OCF of Puma Biotechnology was 668.22. The lowest was -427.82. And the median was 5.16.
PBYI's EV-to-OCF is ranked worse than 81.01% of 1411
companies
in the Biotechnology industry
Industry Median: -3.32
vs PBYI: 5.71
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Puma Biotechnology's PE Ratio (TTM) for today is calculated as:
Puma Biotechnology's share price for today is $7.69.
Puma Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Puma Biotechnology EV-to-OCF Related Terms
Puma Biotechnology EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Puma Biotechnology's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's EV-to-OCF falls into.
Puma Biotechnology's current Enterprise Value is $305.8 Mil.
Puma Biotechnology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $53.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology (PBYI) has a EV-to-OCF of 5.71 as of Aug. 04, 2026. This is 11% above median its historical median of 5.16. According to the industry distribution chart, Puma Biotechnology ranks #1143 out of 1411 companies in the Biotechnology industry, placing it in the top 81%.
Is Puma Biotechnology's EV-to-OCF too high?
Puma Biotechnology's current EV-to-OCF of 5.71 is 11% above median its 10-year median of 5.16. Based on the distribution chart, Puma Biotechnology ranks #1143 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's EV-to-OCF compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #1143 out of 1411 companies for EV-to-OCF. This places Puma Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Puma Biotechnology's current EV-to-OCF is 5.71, which is 11% above median its own 10-year median of 5.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.69 — trading 130.2% above its estimated fair value. The current EV-to-OCF is 5.71, which is 11% above median its 10-year median of 5.16. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current EV-to-OCF is 5.71 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
EV-to-OCF: 5.71 (11% above median its 10-year median of 5.16)
GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
